Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801: Says New Data Show Tolerability And No Evidence Of Spreading To Blood Or Tissues Even At High Doses Of Tonix's Attenuated Live-virus, Minimally Replicating Vaccine Candidate Tnx-801 In Immunocompromised Animals
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals presented promising data on its potential Mpox vaccine, TNX-801, showing tolerability and no evidence of spreading to blood or tissues even at high doses in immunocompromised animals.
November 01, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' TNX-801 vaccine candidate shows promising results in preclinical studies, indicating potential for further development and positive market reaction.
The positive preclinical data on TNX-801 suggests potential for further development, which could lead to increased investor confidence and a positive impact on Tonix Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100